GSK PLC

GSK PLC is navigating a mixed bag of developments, with promising advancements in oncology and antibiotics, but facing challenges in the market and regulatory environment.

GSK PLC has made significant strategic moves, including the acquisition of efimosfermin for up to $2 billion, to bolster its position in the healthcare sector and address critical health issues.